The biotech has named Jamie Coleman its chief commercial officer, per a Monday announcement, putting her in charge of the ...

FDA formally announced the end of the tirzepatide shortage in a Declaratory Order issued to Eli Lilly & Co. (“Lilly”). Lilly ...

Lean mass constituted 30.8% of total body weight lost for adults who received a GLP-1 drug during a randomized controlled ...

Global commercial executive with expertise across product lifecycle and therapeutic areas leading transformative brands, ...

The data appeared to slam the door on the idea that the advent of GLP-1 drugs would eliminate demand for drugs specifically ...

Novo Nordisk announced positive trial results for its next-generation obesity drug, leading to a 7.13% surge in its share ...

Metsera has set its sights on a hefty $289 million IPO as the next-gen obesity biotech seeks to fund a phase 3 trial of its ...

Akero Therapeutics has hit a home run, reporting statistically significant results in two key 96-week metabolic ...

which is sold by Lilly as Mounjaro for diabetes and Zepbound for obesity, have actually been resolved, as reported earlier this month. Under US law, compounding pharmacies can make and sell patent ...

as well as newly-approved obesity therapy Zepbound (tirzepatide). In common with Novo Nordisk’s semaglutide-based diabetes and obesity therapies – respectively Ozempic and Wegovy – Lilly has ...

Tori Allen says she’s thrilled to have lost 80 pounds since she went on Wegovy, one of the GLP-1 drugs that more and more ...

Today show presenter Alex Cullen has taken to social media after he was sacked from Channel Nine over a $50,000 gift from billionaire Adrian Portelli. Aussie billionaire Adrian Portelli has ...